-
Something wrong with this record ?
The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns
I. Türbachova, T. Schwachula, I. Vasconcelos, A. Mustea, T. Baldinger, KA. Jones, H. Bujard, A. Olek, K. Olek, K. Gellhaus, I. Braicu, D. Könsgen, C. Fryer, E. Ravot, A. Hellwag, N. Westerfeld, OJ. Gruss, M. Meissner, MT. Hasan, M. Weber, U....
Language English Country United States
Document type Journal Article
NLK
Free Medical Journals
from 2006 to 1 year ago
PubMed Central
from 2010
Europe PubMed Central
from 2010 to 1 year ago
PubMed
24071829
DOI
10.4161/epi.26334
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Epigenesis, Genetic MeSH
- Immune Tolerance * MeSH
- Colorectal Neoplasms immunology pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Young Adult MeSH
- Biomarkers, Tumor immunology MeSH
- Kidney Neoplasms immunology pathology MeSH
- Lung Neoplasms immunology pathology MeSH
- Breast Neoplasms immunology pathology MeSH
- Ovarian Neoplasms immunology pathology MeSH
- Neoplasms immunology pathology MeSH
- Aged MeSH
- Case-Control Studies MeSH
- T-Lymphocytes immunology pathology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
The adaptive immune system is involved in tumor establishment and aggressiveness. Tumors of the ovaries, an immune-privileged organ, spread via transceolomic routes and rarely to distant organs. This is contrary to tumors of non-immune privileged organs, which often disseminate hematogenously to distant organs. Epigenetics-based immune cell quantification allows direct comparison of the immune status in benign and malignant tissues and in blood. Here, we introduce the "cellular ratio of immune tolerance" (immunoCRIT) as defined by the ratio of regulatory T cells to total T lymphocytes. The immunoCRIT was analyzed on 273 benign tissue samples of colorectal, bronchial, renal and ovarian origin as well as in 808 samples from primary colorectal, bronchial, mammary and ovarian cancers. ImmunoCRIT is strongly increased in all cancerous tissues and gradually augmented strictly dependent on tumor aggressiveness. In peripheral blood of ovarian cancer patients, immunoCRIT incrementally increases from primary diagnosis to disease recurrence, at which distant metastases frequently occur. We postulate that non-pathological immunoCRIT values observed in peripheral blood of immune privileged ovarian tumor patients are sufficient to prevent hematogenous spread at primary diagnosis. Contrarily, non-immune privileged tumors establish high immunoCRIT in an immunological environment equivalent to the bloodstream and thus spread hematogenously to distant organs. In summary, our data suggest that the immunoCRIT is a powerful marker for tumor aggressiveness and disease dissemination.
Charité Universitätsmedizin Berlin Campus Virchow
Clinics for Obstetrics and Gynecology
Department of Molecular Neurobiology
Department of Obstetrics and Gynecology
Division of Infection and Immunity
Erasmus University Medical Center Daniel den Hoed Cancer Center Dept Medical Oncology
Glasgow Biomedical Research Centre
Gray Institute for Radiation Oncology and Biology
Institute of Biomedical Life Sciences
Labor für Abstammungsbegutachtung
Max Planck Institute for Medical Research
Nephrologie und internistische Intensivmedizin
PATHOTRES Gemeinschaftspraxis für Pathologie und Neuropathologie
The Salk Institute for Biological Studies
University Medical Center Hamburg Eppendorf
University Medicine Charité Campus Virchow
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15008559
- 003
- CZ-PrNML
- 005
- 20150424121623.0
- 007
- ta
- 008
- 150306s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.4161/epi.26334 $2 doi
- 035 __
- $a (PubMed)24071829
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Türbachova, Ivana $u Epiontis GmbH; Berlin, Germany.
- 245 14
- $a The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns / $c I. Türbachova, T. Schwachula, I. Vasconcelos, A. Mustea, T. Baldinger, KA. Jones, H. Bujard, A. Olek, K. Olek, K. Gellhaus, I. Braicu, D. Könsgen, C. Fryer, E. Ravot, A. Hellwag, N. Westerfeld, OJ. Gruss, M. Meissner, MT. Hasan, M. Weber, U. Hoffmüller, S. Zimmermann, C. Loddenkemper, S. Mahner, N. Babel, E. Berns, R. Adams, R. Zeilinger, U. Baron, I. Vergote, T. Maughan, F. Marme, T. Dickhaus, J. Sehouli, S. Olek,
- 520 9_
- $a The adaptive immune system is involved in tumor establishment and aggressiveness. Tumors of the ovaries, an immune-privileged organ, spread via transceolomic routes and rarely to distant organs. This is contrary to tumors of non-immune privileged organs, which often disseminate hematogenously to distant organs. Epigenetics-based immune cell quantification allows direct comparison of the immune status in benign and malignant tissues and in blood. Here, we introduce the "cellular ratio of immune tolerance" (immunoCRIT) as defined by the ratio of regulatory T cells to total T lymphocytes. The immunoCRIT was analyzed on 273 benign tissue samples of colorectal, bronchial, renal and ovarian origin as well as in 808 samples from primary colorectal, bronchial, mammary and ovarian cancers. ImmunoCRIT is strongly increased in all cancerous tissues and gradually augmented strictly dependent on tumor aggressiveness. In peripheral blood of ovarian cancer patients, immunoCRIT incrementally increases from primary diagnosis to disease recurrence, at which distant metastases frequently occur. We postulate that non-pathological immunoCRIT values observed in peripheral blood of immune privileged ovarian tumor patients are sufficient to prevent hematogenous spread at primary diagnosis. Contrarily, non-immune privileged tumors establish high immunoCRIT in an immunological environment equivalent to the bloodstream and thus spread hematogenously to distant organs. In summary, our data suggest that the immunoCRIT is a powerful marker for tumor aggressiveness and disease dissemination.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádory prsu $x imunologie $x patologie $7 D001943
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a kolorektální nádory $x imunologie $x patologie $7 D015179
- 650 _2
- $a epigeneze genetická $7 D044127
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a imunologická tolerance $7 D007108
- 650 _2
- $a nádory ledvin $x imunologie $x patologie $7 D007680
- 650 _2
- $a nádory plic $x imunologie $x patologie $7 D008175
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a nádory $x imunologie $x patologie $7 D009369
- 650 _2
- $a nádory vaječníků $x imunologie $x patologie $7 D010051
- 650 _2
- $a T-lymfocyty $x imunologie $x patologie $7 D013601
- 650 _2
- $a nádorové biomarkery $x imunologie $7 D014408
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Schwachula, Tim $u Epiontis GmbH; Berlin, Germany.
- 700 1_
- $a Vasconcelos, Ines $u Epiontis GmbH; Berlin, Germany.
- 700 1_
- $a Mustea, Alexander $u Clinics for Obstetrics and Gynecology; University Greifswald; Greifswald, Germany.
- 700 1_
- $a Baldinger, Tina $u Epiontis GmbH; Berlin, Germany.
- 700 1_
- $a Jones, Katherine A $u Regulatory Biology Laboratory; The Salk Institute for Biological Studies; La Jolla, CA USA.
- 700 1_
- $a Bujard, Hermann $u Zentrum für Molekulare Biologie Heidelberg; INF 282; University Heidelberg; Heidelberg, Germany.
- 700 1_
- $a Olek, Alexander $u Nobel Education; Schönau am Königssee, Germany.
- 700 1_
- $a Olek, Klaus $u Labor für Abstammungsbegutachtung; Prague, Czech Republic.
- 700 1_
- $a Gellhaus, Katharina $u Epiontis GmbH; Berlin, Germany.
- 700 1_
- $a Braicu, Ioana $u Clinics for Obstetrics and Gynecology; University Medicine Charité Campus Virchow; Berlin, Germany.
- 700 1_
- $a Könsgen, Dominique $u Clinics for Obstetrics and Gynecology; University Greifswald; Greifswald, Germany.
- 700 1_
- $a Fryer, Christy $u Novartis; Cambridge, MA USA.
- 700 1_
- $a Ravot, Elisabetta $u Saatchi & Saatchi Health; Milan, Italy.
- 700 1_
- $a Hellwag, Alexander $u Epiontis GmbH; Berlin, Germany.
- 700 1_
- $a Westerfeld, Nicole $u IDEXX Laboratories; Basel, Switzerland.
- 700 1_
- $a Gruss, Oliver J $u DKFZ-ZMBH Allianz; Zentrum für Molekulare Biologie Heidelberg; University Heidelberg; Heidelberg, Germany.
- 700 1_
- $a Meissner, Markus $u Division of Infection and Immunity; Institute of Biomedical Life Sciences; Wellcome Centre for Molecular Parasitology; Glasgow Biomedical Research Centre; University of Glasgow; Glasgow, UK.
- 700 1_
- $a Hasan, Mazahir T $u Department of Molecular Neurobiology; Max Planck Institute for Medical Research; Heidelberg, Germany.
- 700 1_
- $a Weber, Michael $u Epiontis GmbH; Berlin, Germany.
- 700 1_
- $a Hoffmüller, Ulrich $u Epiontis GmbH; Berlin, Germany.
- 700 1_
- $a Zimmermann, Sven $u Epiontis GmbH; Berlin, Germany.
- 700 1_
- $a Loddenkemper, Christoph $u PATHOTRES Gemeinschaftspraxis für Pathologie und Neuropathologie; Berlin, Germany.
- 700 1_
- $a Mahner, Sven $u Department of Gynecology; University Medical Center Hamburg-Eppendorf; Hamburg, Germany.
- 700 1_
- $a Babel, Nina $u Nephrologie und internistische Intensivmedizin; Charité Universitätsmedizin Berlin Campus Virchow; Berlin, Germany.
- 700 1_
- $a Berns, Els $u Erasmus University Medical Center- Daniel den Hoed Cancer Center Dept Medical Oncology; Rotterdam, The Netherlands.
- 700 1_
- $a Adams, Richard $u School of Medicine; Cardiff University; Cardiff, UK. $7 gn_A_00001602
- 700 1_
- $a Zeilinger, Robert $u Molecular Oncology Group; Medical University of Vienna; Vienna, Austria.
- 700 1_
- $a Baron, Udo $u Epiontis GmbH; Berlin, Germany.
- 700 1_
- $a Vergote, Ignace $u Department of Obstetrics and Gynecology; University of Leuven; Leuven, Belgium.
- 700 1_
- $a Maughan, Tim $u Gray Institute for Radiation Oncology and Biology; University of Oxford; Oxford, UK.
- 700 1_
- $a Marme, Frederik $u Department of Gynecology; University of Heidelberg; Heidelberg, Germany.
- 700 1_
- $a Dickhaus, Thorsten $u Department of Mathematics; Humboldt University; Berlin, Germany.
- 700 1_
- $a Sehouli, Jalid $u Clinics for Obstetrics and Gynecology; University Medicine Charité Campus Virchow; Berlin, Germany.
- 700 1_
- $a Olek, Sven $u Epiontis GmbH; Berlin, Germany.
- 773 0_
- $w MED00180218 $t Epigenetics official journal of the DNA Methylation Society $x 1559-2308 $g Roč. 8, č. 11 (2013), s. 1226-35
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24071829 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150306 $b ABA008
- 991 __
- $a 20150424121924 $b ABA008
- 999 __
- $a ok $b bmc $g 1065832 $s 891359
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 8 $c 11 $d 1226-35 $i 1559-2308 $m Epigenetics. $n Epigenetics $x MED00180218
- LZP __
- $a Pubmed-20150306
